Skip to main content

04.10.2022 | Heart Failure (HJ Eisen, Section Editor)

Emerging Therapeutic Targets for Heart Failure

verfasst von: Maneesha Sharma, Lokesh Kumar Bhatt

Erschienen in: Current Cardiology Reports

Einloggen, um Zugang zu erhalten


Purpose of Review

Heart failure is a global epidemic that affects at least 26 million individuals globally and is becoming more prevalent. Despite advances in treatment strategies, survival and symptom management in individuals with heart failure remain exceptionally low. This review discusses emerging targets for the treatment of heart failure.

Recent Findings

Recently, a number of targets are being investigated as prospective treatment possibilities for heart failure. These include targets like Runx1 transcription factor (RUNX1), milk fact globule-EFG factor 8 (MFGE8) protein and enzymes such as neuraminidase 1 (NEU1), G protein–coupled receptor kinase 5 (GRK5), G protein–coupled oestrogen receptor 1 (GPER1), urotensin-II receptor (UTR), cluster of differentiation 47 (CD47) and relaxin receptor 1 (RXFP1).


On a worldwide level, heart failure is a developing epidemic with substantial morbidity and death. The number of individuals diagnosed with chronic heart failure is rising, and it is anticipated to surge by 46% by 2030. Appropriate heart failure treatment can have the greatest influence on prolonging patients’ lives in the coming year. Targets discussed in this review may provide new therapeutic approaches for the treatment of heart failure.

    Emerging Therapeutic Targets for Heart Failure
    verfasst von
    Maneesha Sharma
    Lokesh Kumar Bhatt
    Springer US
    Erschienen in
    Current Cardiology Reports
    Print ISSN: 1523-3782
    Elektronische ISSN: 1534-3170


    Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.